Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals
June 15, 2011

Otsuka receives approval for Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae HS (otitis media/sinusitis)" as in vitro diagnostic on June 13

Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that it obtained approval for manufacturing and marketing of its Streptococcus pneumoniae antigen detection reagent by the immunochromatographic method, "RAPIRUN S. pneumoniae HS (otitis media/sinusitis)" as an in vitro diagnostic on June 13, 2011.